Conquering Diseases

Study Of An Investigational Drug For High Or Very High Risk Myelodysplastic Syndrome

Description

Seeking men and women aged 18 and older who have been diagnosed with intermediate, high, or very high risk myelodysplastic Syndrome for a study of an investigational drug added to standard treatment.

Overview

Participants in this study will have about 40 office visits over about 4 years. All participants will receive the investigational drug in combination with standard treatment for myelodysplastic syndrome (MDS) provided in 28-day cycles.

What we're hoping for

We are studying whether adding an investigational drug to the standard treatment is safe and effective for people who have been diagnosed with intermediate, high, or very high risk myelodysplastic syndrome (MDS).

Additional Information

ClinicalTrials.gov Identifier: NCT04878432

 Principal Investigator

Jonathan M. Gerber, MD

University of Massachusetts Medical School

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989